Oruka Therapeutics
As of the edition of 20 October 2026, Oruka Therapeutics runs 6 drugs; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- ARCA Biopharma, Inc.: merged in 2024; successor Oruka Therapeutics, Inc.
Drugs by status
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 6 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Oruka Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Heart and blood vessels: 11 trials led
- Infections: 2 trials led
- Cancer: 1 trials led